Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.
about
Epigenetic regulators and their impact on therapy in acute myeloid leukemiaFunctions of TET Proteins in Hematopoietic TransformationConnections between TET proteins and aberrant DNA modification in cancerThe TET2 interactors and their links to hematological malignanciesRole of TET enzymes in DNA methylation, development, and cancerDiverse involvement of EZH2 in cancer epigeneticsCAPRI: efficient inference of cancer progression models from cross-sectional data.Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation.Regulation and Role of EZH2 in CancerThe methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancersMyelodysplasia is in the niche: novel concepts and emerging therapies.The molecular basis of myeloid malignancies.SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition.SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.TET proteins and 5-methylcytosine oxidation in hematological cancersPhosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.DNA methylation and hydroxymethylation in hematologic differentiation and transformation.Targeting EZH2 and PRC2 dependence as novel anticancer therapy.Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic LeukemiaDNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in miceLoss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.DNA-PK-mediated phosphorylation of EZH2 regulates the DNA damage-induced apoptosis to maintain T-cell genomic integrityPeripheral blood cell-free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes.Epigenetics of hematopoiesis and hematological malignancies.RNA splicing factors as oncoproteins and tumour suppressors.Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.Stem cell origin of myelodysplastic syndromes.Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.EZH2: an emerging role in melanoma biology and strategies for targeted therapy.The mechanistic role of DNA methylation in myeloid leukemogenesis.Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination-7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity.Epigenetics of hematopoietic stem cell aging and disease.New themes in the biological functions of 5-methylcytosine and 5-hydroxymethylcytosine.Epigenetic modifiers in normal and malignant hematopoiesis.Context-dependent actions of Polycomb repressors in cancer.Therapy-related myeloid neoplasms: when genetics and environment collide.Stem and progenitor cell alterations in myelodysplastic syndromes.
P2860
Q26765402-48758027-4EDC-4E81-9A55-D4DB09DBA6BEQ26778323-5B499753-9244-4D26-B4A1-DF5586CE0B6EQ26865671-70C036BF-0AA9-4BB2-B774-BFCF653A023AQ27002485-40A4AF0D-F907-4EF6-BD8E-F45CADF8B3EEQ28068541-CC0E211A-6082-4D4E-8FBC-F9B644540218Q28084911-0068964A-E4F8-4132-BFDA-7720CAB4919DQ30951310-48668183-96E7-4572-9529-1235D8F27AA5Q33769072-A663C42C-60E0-40A4-A605-D18AFAA2205BQ33934784-A07604CE-68B8-459B-9902-4ADCCB34AC0DQ34043370-D76D53A2-5F7F-4871-ADE0-52FA79F9BDB8Q34861658-03EAD78C-690A-4F9F-8CF3-378C06B8AC07Q35059425-441B4DF2-2571-405B-A7DD-67E2DA5CFF1BQ35103708-9BE7A9D0-57F9-4462-8E58-9E06BC316346Q35601110-34A02784-E20F-40B4-A672-995A10EEBEECQ35849733-C39B64CB-2950-4E9B-B9B1-4B9EB2E4709DQ36197509-0D928333-D4A3-40A0-9F93-695700EF0044Q36335870-683130E9-287C-480B-A44A-861B32598640Q36395976-F5B562EE-16DA-41BC-A42B-FFBFC257CBE0Q36445523-6B97A844-819F-4502-B0CD-A735D15296EFQ36682938-102A1FDB-C734-4AC3-ABA5-EE2254E725DDQ36908743-6B738D46-84F2-4236-A227-60FE0B32F633Q37058122-4CA5BD1D-7E32-4D19-AF78-A62F255AAD4DQ37151491-1E75094C-A610-4D5B-B638-897233515251Q37252302-8374FDF4-C372-480B-9E09-AF557F0A9094Q37343797-117E9502-19EC-4B50-8457-0A65ECA26162Q37391660-D259CE02-6AE8-4428-AAF7-9A18B776C6F2Q37555785-C68E9331-CF59-42FF-A10C-CC1B8320ED0FQ37708968-B6F9DA29-653A-47D1-BA37-504EAB64FEDDQ38171230-170FE6DD-CD98-481A-8231-956F5972E179Q38218055-EFC2A8D3-893A-4B45-89E4-4F5179BF2635Q38218836-19CDBC7E-643D-4764-9922-A98C1E95B9FBQ38218971-1DFB88BE-8F80-4807-AE4C-34937E4E9826Q38225521-879D4DEB-3F74-4342-A04E-D29BCEE867D7Q38226741-788EB0AA-CEBE-4120-B2D6-83FA62B29194Q38235887-406AFA1C-EA2E-40EB-9007-4E40D3FFCF54Q38289020-68D3A3F9-C2C2-485B-A0ED-2CBABF171913Q38459868-FAEC6EA7-99CE-43D7-B2FD-ABA6B7258749Q38518851-1AF3C32C-3251-4366-ABFD-7E5ABF30E678Q38611096-C85EF6A6-8CFA-43DB-811B-3C630C4EAD48Q38761791-0FE97964-DA71-45B0-8D74-939131C8F321
P2860
Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Concurrent loss of Ezh2 and Te ...... of myelodysplastic disorders.
@en
type
label
Concurrent loss of Ezh2 and Te ...... of myelodysplastic disorders.
@en
prefLabel
Concurrent loss of Ezh2 and Te ...... of myelodysplastic disorders.
@en
P2093
P2860
P356
P1476
Concurrent loss of Ezh2 and Te ...... of myelodysplastic disorders.
@en
P2093
Asuka Kamio
Atsunori Saraya
Atsushi Iwama
Chiaki Nakaseko
Genta Nagae
George R Wendt
Goro Sashida
Hiroyuki Aburatani
Kazuya Shimoda
Koutaro Yokote
P2860
P304
P356
10.1084/JEM.20131144
P407
P577
2013-11-11T00:00:00Z